Skip to content
OpenCapital
Get started

TriSalus Life Sciences, Inc. TLSI Enterprise value

Enterprise value at other companies

Boston Scientific logo
Boston ScientificBSX
$141.04B-1.0%
AngioDynamics logo
AngioDynamicsANGO
$441.62M+30.5%
Delcath Systems logo
Delcath SystemsDCTH
$282.05M-31.8%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
$534.65M+98.1%
LQD
Liquidia CorporationLQDA
$3.11B+184%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$787.38M+114%

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%—
Debt / equity2.6×—
Current ratio5.8×+3.6×

Where this comes from

Calculated from TriSalus Life Sciences, Inc.’s reported figures.

$245.2Mmarket cap+$33.1Mtotal debt−$56.6Mcash and equivalents=$221.75M

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s enterprise value?
TriSalus Life Sciences, Inc. (TLSI) reported enterprise value of $221.75M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s enterprise value changed year-over-year?
TriSalus Life Sciences, Inc.'s enterprise value increased by 16.1% year-over-year, from $191.01M to $221.75M.
What is the long-term trend for TriSalus Life Sciences, Inc.'s enterprise value?
Over 2 years (2023 to 2025), TriSalus Life Sciences, Inc.'s enterprise value has grown at a 129.4% compound annual growth rate (CAGR), from $68.86M to $362.4M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.